Growth hormone
Lonapegsomatropin
A sustained-release growth hormone prodrug with distinct pediatric growth and adult body-composition trial evidence in diagnosed GH deficiency.
Randomized pediatric and adult GH-deficiency trials
Also known as: Skytrofa · Lonapegsomatropin-tcgd
Practical use
Clinical context and evidence interpretation
- Separate child and adult evidence
- Identify whether the study measures growth velocity, body composition, symptoms or function before comparing claims.
- Improve the lab record
- Keep IGF-1 results with date, product name and timing information supplied to the clinical team.
- Define more than one success measure
- Ask how symptoms, function, growth or body composition and adverse effects will be considered together.
Overview
Lonapegsomatropin releases unmodified somatropin from a temporary carrier. US Skytrofa is indicated for GH-deficient adults and for children from age one who weigh at least 11.5 kg and have growth failure from inadequate GH secretion. It is not interchangeable with other long-acting GH molecules.
Risks and limitations
GH-related risks include glucose intolerance, fluid retention, intracranial hypertension and changes in thyroid or adrenal needs. Active malignancy and certain acute critical illnesses are contraindications. Persistent severe headache with visual symptoms, or a new limp or hip/knee pain in a child, requires prompt assessment.
How to read this
Children were assessed for growth; adults were assessed for body composition. Lean mass includes more than contractile muscle, and neither endpoint establishes performance enhancement in healthy people.
Research explained
heiGHt: pediatric growth
Who was studied
161 previously untreated prepubertal children with GH deficiency, randomized 2:1 to lonapegsomatropin or daily somatropin in a 52-week open-label active comparison.
What was found
Adjusted annualized height velocity was 11.2 versus 10.3 cm/year. Noninferiority and then superiority were demonstrated. Height-standard-deviation scores improved by 1.10 versus 0.96.
What it cannot establish
One-year height velocity does not equal final adult height. This result cannot establish benefit in a child without the studied disorder or an adult with closed growth plates.
Read the original studyforesiGHt: adult replacement
Who was studied
259 adults with GH deficiency randomized to lonapegsomatropin, placebo or daily somatropin for 38 weeks; placebo comparison blinded, active comparison open-label.
What was found
Compared with placebo, adjusted trunk-fat percentage changed by −1.68 versus +0.37 percentage points; total lean mass changed by +1.60 versus −0.11 kg. The placebo-adjusted lean-mass difference was 1.70 kg.
What it cannot establish
The trial studied hormone replacement in deficiency. Lean-mass measurement is not a direct strength or muscle-fiber outcome, and these averages do not establish healthy-user benefits.
Read the original studyRelease technology does not change the clinical question
The carrier prolongs delivery of somatropin. Evidence still needs to match the diagnosis and the outcome of interest.
Supporting sourceKeep laboratory timing attached to IGF-1
IGF-1 changes across the interval after a long-acting product. A result without the product name and time since administration can be difficult to compare with another result.
Supporting sourceClaims versus findings
Not established
The adult lean-mass result proves the same gain in healthy lifters.
Participants had diagnosed GH deficiency, and the endpoint did not directly measure new contractile muscle or strength.
Check the evidenceCommon questions
Does the pediatric growth result prove a final-height advantage?
No. The cited comparison measured annualized growth over 52 weeks. Final height requires longer follow-up.
SourceSources
US prescribing information; checked October 1, 2026
Sources checked 2026-10-01.
General education; not a personal treatment plan.